Moreover, previous clinical trials also demonstrated that IFN-γ application led to tumor regression and prolonged the progression-free survival of OC patients [15,36], highlighting the therapeutic potential of IFN-γ in OC. The gene discussed is IFNG; the disease is neoplasm.